We are investigating Edge Therapeutics, Inc. (“Edge” or the “Company”) (NasdaqGS:EDGE) relating to the sale of the Company to PDS Biotechnology Corporation. As a result of the transaction, Edge Therapeutics shareholders will own 30% of the combined company.t